Research Analysts Set Expectations for UNCY Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Unicycive Therapeutics to a loss of $0.40 from $0.31, while maintaining a Buy rating and a $15 price target.
• Analyst sentiment is mixed: five firms rate the stock Buy and two rate it Sell, resulting in a consensus Hold rating and an average price target of $18.25.
• Unicycive recently reported a Q2 EPS loss of $0.06, beating estimates for a $0.47 loss. Shares opened at $5.51, well below the consensus target, while institutional investors own 40.42% of the company.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.40) for the quarter, down from their previous estimate of ($0.31). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Unicycive Therapeutics' Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.43) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at $1.98 EPS, FY2029 earnings at $3.08 EPS and FY2030 earnings at $3.11 EPS.

Several other equities analysts have also recently issued reports on UNCY. Weiss Ratings upgraded Unicycive Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, June 9th. Benchmark cut their target price on shares of Unicycive Therapeutics from $18.00 to $13.00 and set a "speculative buy" rating on the stock in a research note on Wednesday, July 1st. Wall Street Zen raised shares of Unicycive Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. B. Riley Financial reiterated a "buy" rating and issued a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday. Finally, Zacks Research cut shares of Unicycive Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 21st. Five equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $18.25.

Unicycive Therapeutics Price Performance

Shares of NASDAQ UNCY opened at $5.51 on Monday. The company has a market cap of $153.45 million, a price-to-earnings ratio of -3.15 and a beta of 1.79. The stock's 50-day moving average is $5.94 and its two-hundred day moving average is $6.64. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.41.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors have recently bought and sold shares of UNCY. State Street Corp raised its position in shares of Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company's stock worth $376,000 after acquiring an additional 10,400 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics in the second quarter valued at approximately $55,000. JPMorgan Chase & Co. increased its stake in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock valued at $104,000 after purchasing an additional 21,525 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Unicycive Therapeutics in the first quarter valued at approximately $161,000. Finally, Bank of America Corp DE increased its stake in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock valued at $194,000 after purchasing an additional 29,378 shares during the last quarter. 40.42% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $15 price target, substantially above the stock’s recent trading level. The firm slightly improved its FY2026 EPS forecast to a $1.43 loss from a $1.45 loss, signaling a marginally better near-term outlook.
• Positive Sentiment: Noble Financial made several favorable near-term revisions, raising its Q3 2026 forecast to a $0.23 loss from a $0.35 loss and its Q4 2026 forecast to a $0.25 loss from a $0.38 loss. Noble also improved its FY2026 forecast to a $0.62 loss from a $1.62 loss. Noble Financial Analysts Lower Earnings Estimates for UNCY
• Neutral Sentiment: Noble Financial lowered its Q1 2027 EPS estimate to $0.64 from $0.85 and its FY2027 estimate to $3.70 from $4.33, although it still projects a transition to profitability in 2027.
• Neutral Sentiment: Wall Street Zen raised Unicycive to a Hold rating, suggesting a more balanced stance on the shares. Unicycive Therapeutics Raised to Hold at Wall Street Zen
• Negative Sentiment: HC Wainwright reduced multiple forecasts, including Q3 and Q4 2026 EPS to losses of $0.40 and $0.42, respectively, and FY2027 EPS to a $1.05 loss from a $0.37 loss.
• Negative Sentiment: HC Wainwright also cut its projected long-term profitability: FY2028 EPS fell to $1.98 from $3.04, FY2029 to $3.08 from $4.57, and FY2030 to $3.11 from $5.42. These revisions imply slower earnings growth, despite the unchanged Buy rating and $15 target.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source